Origin of report

Party	France
Contact officer for report	
Name and title of contact officer:	Bérangère BASIN Chargée de mission Biotechnologies
Mailing address:	Ministère de l'Ecologie et du Développement Durable DPPR / SEI / BBIAA 20 avenue de Ségur 75302 Paris 07 SP FRANCE
Telephone:	+33 (0)1 42 19 14 52
Fax:	+33 (0)1 42 19 14 67
E-mail:	berangere.basin@ecologie.gouv.fr
Submission	
Signature of officer responsible for submitting report:	
Date of submission:	

Please provide summary information on the process by which this report has been prepared, including information on the types of stakeholders who have been actively involved in its preparation and on material which was used as a basis for the report:

Obligations for provision of information to the Biosafety Clearing-House

1. Several articles of the Protocol require that information be provided to the Biosafety Clearing-House (see the list below). For your Government, if there are cases where relevant information exists but has not been provided to the BCH, describe any obstacles or impediments encountered regarding provision of that information (note: To answer this question, please check the BCH to determine the current status of your country's information submissions relative to the list of required information below. If you do not have access to the BCH, contact the Secretariat for a summary):
- Une grande partie de l'information requise provient du niveau européen. Cf. rapport de l'UE. - Concernant les informations nationales spécifiques, qui constituent une masse importante d'informations, la France en a déjà fourni une partie. (- A lot of the required information comes from the European level. Please see EC report. - As for the specific national information, which represents a big amount of information, France has already provided some of the required information.)

Information required to be provided to the Biosafety Clearing-House:

(a) Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20.3(a)***)***

(b) National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11.5);

(c) Bilateral, multilateral and regional agreements and arrangements (Articles 14.2, 20.3(b), and 24.1);

(d) Contact details for competent national authorities (Articles 19.2 and 19.3), national focal points (Articles 19.1 and 19.3), and emergency contacts (Article 17.2 and 17.3(e));

(e) In cases of multiple competent national authorities, responsibilities for each (Articles 19.2 and 19.3);

(f) Reports submitted by the Parties on the operation of the Protocol (Article 20.3(e));

(g) Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17.1);

(h) Illegal transboundary movements of LMOs (Article 25.3);

(i) Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10.3 and 20.3(d));

(j) Information on the application of domestic regulations to specific imports of LMOs (Article 14.4);

(k) Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11.1);

(l) Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11.4) or in accordance with Annex III (Article 11.6) (requirement of Article 20.3(d))

(m) Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11.6)

(n) Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12.1);

(o) LMOs granted exemption status by each Party (Article 13.1)

(p) Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13.1); and

(q) Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20.3(c)).

Article 2 – General provisions

2. Has your country introduced the necessary legal, administrative and other measures for implementation of the Protocol? (Article 2.1)	
a) full domestic regulatory framework in place (please give details below)	X
b) some measures introduced (please give details below)	
c) no measures yet taken	

3. Please provide further details about your response to the above question, as well as description of your country's experiences and progress in implementing Article 2, including any obstacles or impediments encountered:

L'Union européenne a créé un cadre juridique pour assurer la sécurité dans le développement, l'utilisation et le transfert d'OGM. Cf. le rapport de l'UE.

Pour mettre en œuvre le cadre européen au niveau national, la France a développé des outils légaux et réglementaires, en particulier :

(The EC has created a comprehensive legal framework for ensuring safety in the development, use and transfer of GMOs . Please see EC report.
To implement the European framework at national level, France has developed legal and regulatory tools, in particular :)

Texte (Text)
Titre du texte (Title of the text)
Sujet du texte (Topic of the text)

Code de l'Environnement art L 511.1 à L 517.2
Utilisation confinée (Contained Use)

Code de l'Environnement art L 531.1 à L 537.1
Utilisation confinée + dissémination volontaire dans l'environnement
(Contained Use + Deliberate Release into the environment)

Décret 77-1133 modifié par le décret 94-484
Pris pour l'application de la loi 76-663 relative aux installations classées pour la protection de l'environnement
Utilisation confinée – production industrielle
(Contained use - Industrial production)

Décret 93-773
Pris pour l'application s'agissant des utilisations civiles de l'article 6 de la loi 92-654 relative au contrôle de l'utilisation et de la dissémination des OGM et modifiant la loi 76-663 relative aux installations classées pour la protection de l'environnement
Utilisation confinée – objectifs de recherche/expérimentation
(Contained use – Research/experimentation purposes)

Décret 93-774 modifié par les décrets 94-527 et 98-18
Fixant la liste des techniques de modification génétique et les critères de classement des OGM
Classification

Décret 93-1177
Pris pour l'application, s'agissant de plantes, semences et plants, du titre III de la loi 92-654 relative au contrôle de

l'utilisation et de la dissémination des OGM et modifiant la loi 76-663 relative aux installations classées pour la protection de l'environnement
Dissémination volontaire de plants, semences ou plantes génétiquement modifiées à toute autre fin que la mise sur le marché et à fin de mise sur le marché
(Deliberate Release of GM plants for any other purpose than for placing on the market and for placing on the market)

Décret 94-46
Fixant les conditions de dissémination volontaire des OGM destinés à l'alimentation humaine autres que les plantes, les semences, les plants et les animaux, ou entrant dans la composition des produits de nettoyage des matériaux et objets destinés à entrer en contact avec des denrées, produits ou boissons destinés à l'alimentation de l'homme ou des animaux
Dissémination volontaire de produits d'alimentation humaine génétiquement modifiés à toute autre fin que la mise sur le marché et à fin de mise sur le marché
(Deliberate Release of GM Food other than plants for any other purpose than for placing on the market and for placing on the market)

Décret 94-359
Relatif au contrôle des produits pharmaceutiques
Dissémination volontaire de produits phytopharmaceutiques génétiquement modifiés à toute autre fin que la mise sur le marché et à fin de mise sur le marché
(Deliberate Release of GM phytopharmaceutical products for any other purpose than for placing on the market and for placing on the market

Décret 95-487
Pris pour l'application, s'agissant d'animaux génétiquement modifiés du titre III de la loi 92-654 relative au contrôle de l'utilisation et de la dissémination des OGM et modifiant la loi 76-663 relative aux installations classées pour la protection de l'environnement
Dissémination volontaire d'animaux génétiquement modifiés à toute autre fin que la mise sur le marché et à fin de mise sur le marché
(Deliberate Release of GM animals for any other purpose than for placing on the market and for placing on the market)

Décret 95-1172
Pris pour l'application du titre III de la loi 92-654 relative au contrôle de l'utilisation et de la dissémination des OGM, en ce qui concerne les médicaments à usage humain et les produits mentionnés aux 8°, 9° et 10° de l'article L511-1 du Code de la Santé publique
Dissémination volontaire de produits médicaux à usage humain génétiquement modifiés à toute autre fin que la mise sur le marché et à fin de mise sur le marché
(Deliberate Release of GM medicinal products for human use for any other purpose than for placing on the market and for placing on the market)

Décret 95-1173
Pris pour l'application du titre III de la loi 92-654 relative au contrôle de l'utilisation et de la dissémination des OGM, en ce qui concerne les médicaments vétérinaires
Dissémination volontaire de produits médicaux à usage vétérinaire génétiquement modifiés à toute autre fin que la mise sur le marché et à fin de mise sur le marché
(Deliberate Release of GM medicinal products for veterinary use for any other purpose than for placing on the market and for placing on the market)

Décret 96-317
Pris pour l'application du titre III de la loi 92-654 relative au contrôle de l'utilisation et de la dissémination des OGM, en ce qui concerne les éléments ou produits du corps humain génétiquement modifiés après avoir été prélevés ou recueillis
Dissémination volontaire de produits ou d'éléments du corps humain génétiquement modifiés à des fins d'expérimentation

(Deliberate Release for experimentation purposes of products or elements of the human body that have been genetically modified)

Décret 96-850
Relatif au contrôle de la dissémination volontaire et de la mise sur le marché, à des fins civiles, de produits composés en tout ou partie d'OGM
Dissémination volontaire d'OGM à toute autre fin que la mise sur le marché et à fin de mise sur le marché
(Deliberate Release of GMO for any other purpose than for placing on the market and for placing on the market; *for GMOs that do not fall under one of the other decrees*)

Décret 97-685
Pris pour l'application, s'agissant d'alimentation animale, du titre III de la loi 92-654 relative au contrôle de l'utilisation et de la dissémination des OGM et modifiant la loi 76-663 relative aux installations classées pour la protection de l'environnement
Dissémination volontaire de produits d'alimentation animale génétiquement modifiés à toute autre fin que la mise sur le marché et à fin de mise sur le marché
(Deliberate Release of GM Feed other than plants and animals for any other purpose than for placing on the market and for placing on the market)

Décret 98-318
Relatif au contrôle des matières fertilisantes et des supports de culture composés en tout ou partie d'OGM
Dissémination volontaire de produits de fertilisation génétiquement modifiés à toute autre fin que la mise sur le marché et à fin de mise sur le marché
(Deliberate Release of GM fertilizing materials for any other purpose than for placing on the market and for placing on the market)

Arrêté du 27 juillet 1994
portant autorisation de mise sur le marché de semences de la variété de tabac ITB 1000 0X résistant aux herbicides
Consentement écrit (tabac)
(Written consent; tobacco)

Arrêté du 21 septembre 1994
Relatif au dossier de demande de dissémination volontaire dans l'environnement à toute autre fin que la mise sur le marché et au dossier de mise sur le marché de plants, semences ou plantes génétiquement modifiés
(Format of the dossier for deliberate release of GM plants for any other purpose than for placing on the market and for placing on the market)

Arrêté du 27 décembre 1994
Relatif au dossier de demande d'agrément prévu au titre Ier du décret 93-773
Format du dossier pour l'utilisation confinée d'OGM à des fins de recherche/expérimentation
(Format of the dossier for contained use of GMO for Research / experimentation purposes)

Arrêté du 18 juillet 1995
Fixant le contenu des dossiers de demande d'autorisation de dissémination volontaire, à des fins de mise sur le marché ou non, des OGM destinés à l'alimentation humaine autres que les plantes, les semences, les plants et les animaux ou entrant dans la composition des produits de nettoyage, des matériaux et objets destinés à l'alimentation de l'homme ou des animaux
(Format of the dossier for deliberate release of GM Food other than plants for any other purpose than for placing on the market and for placing on the market)

Arrêté du 28 août 1996
Relatif à la composition du dossier d'agrément prévu à l'article 43-1 du décret 77-1133 modifié
Format du dossier pour l'utilisation confinée d'OGM pour la production industrielle
(Format of the dossier for contained use of GMO for industrial production)

Arrêté du 4 février 1997
portant autorisation de mise sur le marché de lignées de maïs (Zea mays L.) génétiquement modifiées protégées contre la pyrale et présentant une tolérance accrue aux herbicides de la famille du glufosinate-ammonium
Consentement écrit (maïs BT176)
(Written consent ; Maize Bt176)

Arrêté du 5 février 1998
Portant modification du Catalogue officiel des espèces et variétés de plantes cultivées en France (semences de maïs)
(Inscription into the French official catalogue ; Bt176 : 3 varieties)

Arrêté du 2 juin 1998
Relatif aux prescriptions générales applicables aux installations classées pour la protection de l'environnement soumises à déclaration sous la rubrique 2680-1.
Utilisation confinée d'OGM : prescriptions générales pour la production industrielle (classe 1)
(Contained use of GMO : General prescriptions for industrial production =; class 1)

Arrêté du 2 juin 1998
Relatif aux règles techniques auxquelles doivent satisfaire les installations soumises à autorisation au titre de la rubrique 2680-2 de la nomenclature des installations classées pour la protection de l'environnement
Utilisation confinée d'OGM : prescriptions générales pour la production industrielle (classe 1)
(Contained use of GMO : General prescriptions for industrial production ; classes 2-3-4)

Arrêté du 3 juin 1998 complété par l'arrêté du 5 février 1999
Portant habilitation des agents à rechercher et constater les infractions aux dispositions relatives à la dissémination volontaire dans l'environnement de produits phytopharmaceutiques, de plantes, semences et plants composés en tout ou partie d'OGM

Arrêté de 3 août 1998
Portant consentement écrit, au titre de l'article 13, §4, de la directive 90/220/CEE, des décisions 98/293/CE et 98/294/CE concernant la mise sur le marché de maïs génétiquement modifié (T25 et MON810)
Consentement écrit (maïs T25 et MON810
(written consent ; Maize T25 and MON810)

Arrêté de 3 août 1998
Portant modification du Catalogue officiel des espèces et variétés de plantes cultivées en France (semences de maïs)
(inscription into the French official catalogue ; Bt176 : 6 varieties and MON810 : 6 varieties)

Arrêté du 23 décembre 1999
Fixant le contenu du dossier technique accompagnant la demande d'autorisation de dissémination volontaire d'OGM dans le cadre d'expérimentations portant sur des médicaments vétérinaires
(Format of the dossier for deliberate release of GM medicinal products for veterinary use for research purposes)

Arrêté du 18 octobre 2000
Fixant le contenu du dossier technique accompagnant la demande d'autorisation de dissémination volontaire d'OGM dans le cadre de recherches biomédicales portant sur des médicaments à usage humain ou des produits mentionnés aux 8°, 9° et 10° de l'article L5121 du Code de la Santé publique
(Format of the dossier for deliberate release of GM medicinal products for human use for research purposes)

Arrêté du 30 novembre 2001
Fixant le contenu du dossier technique accompagnant la demande d'autorisation de dissémination volontaire d'OGM dans le cadre de recherches biomédicales portant sur les éléments et produits du corps humain génétiquement modifiés après avoir été prélevés ou recueillis
(Format of the dossier for deliberate release for experimentation purposes of products or elements of the human body that have been genetically modified)

La France a mis en place 3 comités scientifiques (France has set up 3 scientific comitees):
* Commission de Génie Génétique
* Commission de Génie Biomoléculaire
* Comité Provisoire de Biovigilance

Articles 7 to 10 and 12: The advance informed agreement procedure

Cf. question 1 sur la fourniture d'information au Centre d'échange pour la prévention des risques biotechnologiques

(See question 1 regarding provision of information to the Biosafety Clearing-House.)

4. Is there a legal requirement for the accuracy of information provided by exporters 1/ under the jurisdiction of your country? (Article 8.2)	
a) yes	X
b) no	
c) not applicable – not a Party of export	
5. If you were a Party of export during this reporting period, did you request any Party of import to review a decision it had made under Article 10 on the grounds specified in Article 12.2?	
a) yes (please give details below)	
b) no	
c) not applicable – not a Party of export	X
6. Did your country take decisions regarding import under domestic regulatory frameworks as allowed by Article 9.2(c).	
a) yes	X (for experimental purposes)
b) no	
c) not applicable – no decisions taken during the reporting period	
7. If your country has been a Party of export of LMOs intended for release into the environment during the reporting period, please describe your experiences and progress in implementing Articles 7 to 10 and 12, including any obstacles or impediments encountered:	

1/ The use of terms in the questions follows the meanings accorded to them under Article 3 of the Protocol

8. If your country has taken decisions on import of LMOs intended for release into the environment during the reporting period, please describe your experiences and progress in implementing Articles 7 to 10 and 12, including any obstacles or impediments encountered:
La Communauté européenne applique son cadre législatif propre à la place de la procédure d'accord préalable prévue par le Protocole. Les importations vers la France ont été effectuées à des fins expérimentales et conformément à la législation communautaire : la société qui souhaite introduire des OGM dans l'environnement à des fins expérimentales doit préalablement obtenir l'autorisation écrite de l'autorité compétente. En 2005, 12 nouvelles autorisations de dissémination volontaire à des fins expérimentales ont été émises. (The EC applies its domestic legislative framework instead of the Protocol's advance informed agreement procedure. Please see EC report. The imports in France were for experimental purposes and were done according to EC legislation : The company that wants to introduce GMO into the environment for experimental purposes must first obtain written authorization from the competent authority. In 2005, 12 new authorizations of deliberate releases for experimental purposes were issued.)

Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing

Cf. question 1 sur la fourniture d'information au Centre d'échange pour la prévention des risques biotechnologiques

(See question 1 regarding provision of information to the Biosafety Clearing-House.)

9. Is there a legal requirement for the accuracy of information provided by the applicant with respect to the domestic use of a living modified organism that may be subject to transboundary movement for direct use as food or feed, or for processing? (Article 11.2)	
a) yes	X
b) no	
c) not applicable (please give details below)	
10. Has your country indicated its needs for financial and technical assistance and capacity building in respect of living modified organisms intended for direct use as food or feed, or for processing? (Article 11.9)	
a) yes (please give details below)	
b) no	
c) not relevant	X
11. Did your country take decisions regarding import under domestic regulatory frameworks as allowed by Article 11.4?	
a) yes	X
b) no	

c) not applicable – no decisions taken during the reporting period	

12. If your country has been a Party of export of LMOs intended for direct use for food or feed, or for processing, during the reporting period, please describe your experiences and progress in implementing Article 11, including any obstacles or impediments encountered:
Sans objet. La CE n'était pas une Partie d'exportation pendant la période couverte par le présent rapport. (Not applicable. EC was not a Party of export during the reporting period.)

13. If your country has been a Party of import of LMOs intended for direct use for food or feed, or for processing, during the reporting period, please describe your experiences and progress in implementing Article 11, including any obstacles or impediments encountered:
Cf. rapport de la CE. (Please see EC report)

Article 13 – Simplified procedure

Cf. question 1 sur la fourniture d'information au Centre d'échange pour la prévention des risques biotechnologiques

(See question 1 regarding provision of information to the Biosafety Clearing-House.)

14. If your country has used the simplified procedure during the reporting period, please describe your experiences in implementing Article 13, including any obstacles or impediments encountered:
Cf. rapport de la CE. (Please see EC report)

Article 14 – Bilateral, regional and multilateral agreements and arrangements

Cf. question 1 sur la fourniture d'information au Centre d'échange pour la prévention des risques biotechnologiques

(See question 1 regarding provision of information to the Biosafety Clearing-House.)

15. If your country has entered into bilateral, regional or multilateral agreements or arrangements, describe your experiences in implementing Article 14 during the reporting period, including any obstacles or impediments encountered:
Cf. rapport de la CE. (Please see EC report)

Articles 15 and 16 – Risk assessment and risk management

16. If you were a Party of import during this reporting period, were risk assessments carried out for all decisions taken under Article 10? (Article 15.2)	
a) yes	X Les importations étaient à des fins expérimentales – cf. questions 6 et 8 (the imports were for experimental purposes – see questions 6 and 8)
b) no (please clarify below)	
c) not a Party of import	
17. If yes, did you require the exporter to carry out the risk assessment?	
a) yes – in all cases	X
b) yes – in some cases (please specify the number and give further details below)	
c) no	
d) not a Party of import	
18. If you took a decision under Article 10 during the reporting period, did you require the notifier to bear the cost of the risk assessment? (Article 15.3)	
a) yes – in all cases	
b) yes – in some cases (please specify the number and give further details below)	
c) no	
19. Has your country established and maintained appropriate mechanisms, measures and strategies to regulate, manage and control risks identified in the risk assessment provisions of the Protocol? (Article 16.1)	
a) yes	X
b) no	
20. Has your country adopted appropriate measures to prevent unintentional transboundary movements of living modified organisms? (Article 16.3)	
a) yes	X
b) no	
21. Does your country endeavour to ensure that any living modified organism, whether imported or locally developed, undergoes an appropriate period of observation commensurate with its life-cycle or generation time before it is put to its intended use? (Article 16.4)	
a) yes – in all cases	X
b) yes – in some cases (please give further details below)	

c) no (please give further details below)	
d) not applicable (please give further details below)	
22. Has your country cooperated with others for the purposes specified in Article 16.5?	
a) yes (please give further details below)	X
b) no (please give further details below)	
23. Please provide further details about your responses to the above questions, as well as description of your country's experiences and progress in implementing Articles 15 and 16, including any obstacles or impediments encountered:	
Cf. rapport de la CE. Les évaluations de risque sont d'abord conduites par les entreprises notifiantes. En France, elles sont alors étudiées et évaluées par la Commission du génie biomoléculaire. (Please see EC report - Risk assessments are first carried out by notifiers. In France, they are then studied and evaluated by the Commission du Génie Biomoléculaire)	

Article 17 – Unintentional transboundary movements and emergency measures

Cf. question 1 sur la fourniture d'information au Centre d'échange pour la prévention des risques biotechnologiques

(See question 1 regarding provision of information to the Biosafety Clearing-House.)

24. During the reporting period, if there were any occurrences under your jurisdiction that led, or could have led, to an unintentional transboundary movement of a living modified organism that had, or could have had, significant adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health in such States, did you immediately consult the affected or potentially affected States for the purposes specified in Article 17.4?	
a) yes – all relevant States immediately	
b) partially (please clarify below)	
c) no (please clarify below)	X
25. Please provide further details about your response to the above question, as well as description of your country's experiences in implementing Article 17, including any obstacles or impediments encountered:	
Sans objet (Not applicable)	

Article 18 – Handling, transport, packaging and identification

26. Has your country taken measures to require that living modified organisms that are subject to transboundary movement within the scope of the Protocol are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards? (Article 18.1)	
a) yes (please give details below)	X
b) no	
c) not applicable (please clarify below)	
27. Has your country taken measures to require that documentation accompanying living modified organisms for direct use as food or feed, or for processing, clearly identifies that they 'may contain' living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for information? (Article 18.2(a))	
a) yes	X
b) no	
28. Has your country taken measures to require that documentation accompanying living modified organisms that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the living modified organisms are consigned? (Article 18.2(b))	
a) yes	X
b) no	
29. Has your country adopted measures to require that documentation accompanying living modified organisms that are intended for intentional introduction into the environment of the Party of import and any other living modified organisms within the scope of the Protocol, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter? (Article 18.2(c))	
a) yes	X
b) no	
30. Please provide further details about your responses to the above questions, as well as description of your country's experiences and progress in implementing Article 18, including any obstacles or impediments encountered:	
Cf. rapport de la CE. (Please see EC report)	

Article 19 – Competent national authorities and national focal points

Cf. question 1 sur la fourniture d'information au Centre d'échange pour la prévention des risques biotechnologiques

(See question 1 regarding provision of information to the Biosafety Clearing-House.)

Article 20 – Information-sharing and the Biosafety Clearing-House

Cf. question 1 sur la fourniture d'information au Centre d'échange pour la prévention des risques biotechnologiques

(See question 1 regarding provision of information to the Biosafety Clearing-House.)

31. In addition to the response to question 1, please describe any further details regarding your country's experiences and progress in implementing Article 20, including any obstacles or impediments encountered:
Cf. rapport de la CE. (Please see EC report)

Article 21 – Confidential information

32. Does your country have procedures to protect confidential information received under the Protocol and that protect the confidentiality of such information in a manner no less favourable than its treatment of confidential information in connection with domestically produced living modified organisms? (Article 21.3)	
a) yes	X
b) no	
33. If you were a Party of import during this reporting period, did you permit any notifier to identify information submitted under the procedures of the Protocol or required by the Party of import as part of the advance informed agreement procedure that was to be treated as confidential? (Article 21.1)	
a) yes	
If yes, please give number of cases	
b) no	
c) not applicable – not a Party of import	

34. If you answered yes to the previous question, please provide information on your experience including description of any impediments or difficulties encountered:
Cf. rapport de la CE. (Please see EC report)
35. If you were a Party of export during this reporting period, please describe any impediments or difficulties encountered by you, or by exporters under your jurisdiction if information is available, in the implementation of the requirements of Article 21:

Article 22 – Capacity-building

36. If a developed country Party, during this reporting period has your country cooperated in the development and/or strengthening of human resources and institutional capacities in biosafety for the purposes of the effective implementation of the Protocol in developing country Parties, in particular the least developed and small island developing States among them, and in Parties with economies in transition?	
a) yes (please give details below)	X
b) no	
c) not applicable – not a developed country Party	
37. If yes, how has such cooperation taken place:	
Cf. rapport de la CE et question 55. (Please see EC report and question 55)	
38. If a developing country Party or a Party with an economy in transition, have you benefited from cooperation for technical and scientific training in the proper and safe management of biotechnology to the extent that it is required for biosafety?	
a) yes – capacity-building needs fully met (please give details below)	
b) yes – capacity-building needs partially met (please give details below)	
c) no – capacity-building needs remain unmet (please give details below)	
b) no – we have no unmet capacity-building needs in this area	
e) not applicable – not a developing country Party or a Party with an economy in transition	X
39. If a developing country Party or a Party with an economy in transition, have you benefited from cooperation for technical and scientific training in the use of risk assessment and risk management for biosafety?	
a) yes – capacity-building needs fully met (please give details below)	
b) yes – capacity-building needs partially met (please give details below)	

c) no – capacity-building needs remain unmet (please give details below)	
d) no – we have no unmet capacity-building needs in this area	
e) not applicable – not a developing country Party or a Party with an economy in transition	X
40. If a developing country Party or a Party with an economy in transition, have you benefited from cooperation for technical and scientific training for enhancement of technological and institutional capacities in biosafety?	
a) yes – capacity-building needs fully met (please give details below)	
b) yes – capacity-building needs partially met (please give details below)	
c) no – capacity-building needs remain unmet (please give details below)	
d) no – we have no unmet capacity-building needs in this area	
e) not applicable – not a developing country Party or a Party with an economy in transition	X
41. Please provide further details about your responses to the above questions, as well as description of your country's experiences and progress in implementing Article 22, including any obstacles or impediments encountered:	

Article 23 – Public awareness and participation

42. Does your country promote and facilitate public awareness, education and participation concerning the safe transfer, handling and use of living modified organisms in relation to the conservation and sustainable use of biological diversity, taking also into account risks to human health? (Article 23.1(a))	
a) yes – significant extent	X
b) yes – limited extent	
c) no	
43. If yes, do you cooperate with other States and international bodies?	
a) yes – significant extent	
b) yes – limited extent	X
c) no	
44. Does your country endeavour to ensure that public awareness and education encompass access to information on living modified organisms identified in accordance with the Protocol that may be imported? (Article 23.1(b))	
a) yes – fully	X
b) yes – limited extent	
c) no	

45. Does your country, in accordance with its respective laws and regulations, consult the public in the decision-making process regarding living modified organisms and make the results of such decisions available to the public? (Article 23.2)	
a) yes – fully	X
b) yes – limited extent	
c) no	
46. Has your country informed its public about the means of public access to the Biosafety Clearing-House? (Article 23.3)	
a) yes – fully	
b) yes – limited extent	X
c) no	

47. Please provide further details about your responses to the above questions, as well as description of your country's experiences and progress in implementing Article 23, including any obstacles or impediments encountered:

- Cf. rapport de la CE.
- En outre la France a créé un site Internet national www.ogm.gouv.fr qui fournit des informations sur la réglementation OGM, des actualités, des essais en plein champ…
- Selon la directive 2001/18 (article 9), l'information et la consultation du public à toute autre fin que la mise sur le marché doit être effectuée au niveau national. En France, la procédure suivie pour les essais en plein champ est la suivante:
  - Information des maires des communes où la dissémination volontaire aura lieu;
  - Consultation publique sur le site www.ogm.gouv.fr. Le public dispose de 15 jours pour exprimer des positions/commentaires;
  - Le résultat de la consultation est publié sur le site Internet.
  - Si des décisions d'autorisation sont prises, elles sont publiées sur le site Internet.
  - Des fiches d'information du public sont affichées dans les mairies des communes où les essais en plein champ ont lieu et sont disponibles sur le site Internet;
  - Un tableau résumant tous les essais en plein champ est disponible sur le site Internet.

- En outre, la France est Partie à la convention d'Aarhus sur l'accès à l'information, la participation du public à la prise de décision et l'accès à la justice dans le domaine de l'environnement.

(- Please see EC report

- Moreover, France has created a national website www.ogm.gouv.fr that gives information on GMO regulation, news, field trials, …

- According to Directive 2001/18 (Article 9), public information and consultation for any other purpose than for placing on the market have to be done at national level. In France, the following is done for field trials :
* information of the mayors of the towns where the deliberate release will take place
* public consultation on the website www.ogm.gouv.fr. The public has 15 days to express its opinion / comments
* results of the public consultation are then published on the website
* if decisions of authorization are taken, they are published on the website.
* 'Fiches d'information du public' are put up in the city halls of the town where field trials take place and are displayed on the website
*A table that summarizes all field trials in place is displayed on the website.

- Moreover, France is a Party to the Aarhus Convention on Access to information, public participation in decision-making and access to jucstice in environmental matters.)

Article 24 – Non-Parties

Cf. question 1 sur la fourniture d'information au Centre d'échange pour la prévention des risques biotechnologiques

(See question 1 regarding provision of information to the Biosafety Clearing-House.)

48. If there have been transboundary movements of living modified organisms between your country and a non-Party, please provide information on your experience, including description of any impediments or difficulties encountered:

Article 25 – Illegal transboundary movements

Cf. question 1 sur la fourniture d'information au Centre d'échange pour la prévention des risques biotechnologiques

(See question 1 regarding provision of information to the Biosafety Clearing-House.)

49. Has your country adopted appropriate domestic measures to prevent and penalize, as appropriate, transboundary movements of living modified organisms carried out in contravention of its domestic measures? (Article 25.1)	
a) yes	X
b) no	
50. Please provide further details about your response to the above question, as well as description of your country's experiences in implementing Article 25, including any obstacles or impediments encountered:	
Cf. rapport de la CE (Please see EC report)	

Article 26 – Socio-economic considerations

51. If during this reporting period your country has taken a decision on import, did it take into account socio-economic considerations arising from the impact of living modified organisms on the conservation and sustainable use of biological diversity, especially with regard to the value of biological diversity to indigenous and local communities? (Article 26.1)	
a) yes – significant extent	
b) yes – limited extent	
c) no	

d) not a Party of import	
52. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of living modified organisms, especially on indigenous and local communities? (Article 26.2)	
a) yes – significant extent	
b) yes – limited extent	
c) no	
53. Please provide further details about your responses to the above questions, as well as description of your country's experiences and progress in implementing Article 26, including any obstacles or impediments encountered:	

Article 28 – Financial mechanism and resources

54. Please indicate if, during the reporting period, your government made financial resources available to other Parties or received financial resources from other Parties or financial institutions, for the purposes of implementation of the Protocol.	
a) yes – made financial resources available to other Parties	X
b) yes – received financial resources from other Parties or financial institutions	
c) both	
d) neither	
55. Please provide further details about your response to the above question, as well as description of your country's experiences, including any obstacles or impediments encountered:	
La France a permis à 7 délégués de pays d'Afrique d'assister à la 2e réunion des Parties à Montréal en juin : M. Rodrigue Abourou (Gabon), M. Papa Meïssa Dieng (Sénégal), M. Hassan Bendahmane (Maroc), M. Vincent Kasulu Seya Makonga (RDC), Mme Rabemananjara Harifera Elisa (Madagascar), Mme Hawa Diallo (Guinée Conakry) et Mme Koffi Akissi (Côte d'Ivoire). (France made it possible for 7 delegates from Africa to attend the 2nd meeting of the Parties in Montréal in June: M. Rodrigue Abourou (Gabon), M. Papa Meïssa Dieng (Sénégal), M. Hassan Bendahmane (Maroc), M. Vincent Kasulu Seya Makonga (RDC), Mme Rabemananjara Harifera Elisa (Madagascar), Mme Hawa Diallo (Guinée Conakry) et Mme Koffi Akissi (Côte d'Ivoire).)	

Other information

56. Please use this box to provide any other information related to articles of the Protocol, questions in the reporting format, or other issues related to national implementation of the Protocol:

Comments on reporting format

The wording of these questions is based on the Articles of the Protocol. Please provide information on any difficulties that you have encountered in interpreting the wording of these questions: